Does the media refer more to REGN or INSM?

In the previous week, Regeneron Pharmaceuticals had 36 more articles in the media than Insmed. MarketBeat recorded 41 mentions for Regeneron Pharmaceuticals and 5 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Regeneron Pharmaceuticals' score of 0.51 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regeneron Pharmaceuticals 12 Very Positive mention(s) 7 Positive mention(s) 13 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Insmed 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, INSM or ARGX?

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 39.19 -$1.28B -$4.11 N/A argenex $4.25B 13.57 $1.29B $26.04 35.38

Is INSM or ARGX more profitable?

argenex has a net margin of 32.19% compared to Insmed's net margin of -76.94%. argenex's return on equity of 43.59% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% argenex 32.19% 43.59% 36.66%

Does the media prefer INSM or ARGX?

In the previous week, Insmed had 2 more articles in the media than argenex. MarketBeat recorded 5 mentions for Insmed and 3 mentions for argenex. Insmed's average media sentiment score of 0.59 beat argenex's score of 0.05 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, MRNA or INSM?

Insmed has lower revenue, but higher earnings than Moderna. Insmed is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 38.02 -$2.82B -$7.99 N/A Insmed $606.42M 39.19 -$1.28B -$4.11 N/A

Is MRNA or INSM more profitable?

Insmed has a net margin of -76.94% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Insmed -76.94% -123.94% -44.30%

Does the media favor MRNA or INSM?

In the previous week, Moderna had 40 more articles in the media than Insmed. MarketBeat recorded 45 mentions for Moderna and 5 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Moderna's score of 0.27 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 9 Very Positive mention(s) 16 Positive mention(s) 9 Neutral mention(s) 10 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, NTRA or INSM?

Natera has higher revenue and earnings than Insmed. Natera is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 25.23 -$208.16M -$1.36 N/A Insmed $606.42M 39.19 -$1.28B -$4.11 N/A

Is NTRA or INSM more profitable?

Natera has a net margin of -7.11% compared to Insmed's net margin of -76.94%. Natera's return on equity of -11.38% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Natera -7.11% -11.38% -7.87% Insmed -76.94% -123.94% -44.30%

Does the media favor NTRA or INSM?

In the previous week, Natera had 3 more articles in the media than Insmed. MarketBeat recorded 8 mentions for Natera and 5 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Natera's score of 0.50 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INSM or RVMD?

In the previous week, Revolution Medicines had 11 more articles in the media than Insmed. MarketBeat recorded 16 mentions for Revolution Medicines and 5 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Revolution Medicines' score of 0.57 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Insmed (INSM) Competitors

$108.91 +0.32 (+0.29%)

As of 11:25 AM Eastern

Compare

INSM vs. REGN, ARGX, MRNA, NTRA, and RVMD

Should you buy Insmed stock or one of its competitors? Insmed's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Moderna (MRNA), Natera (NTRA), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Insmed compare to Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals (NASDAQ:REGN) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Regeneron Pharmaceuticals had 36 more articles in the media than Insmed. MarketBeat recorded 41 mentions for Regeneron Pharmaceuticals and 5 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Regeneron Pharmaceuticals' score of 0.51 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regeneron Pharmaceuticals	12 Very Positive mention(s)	7 Positive mention(s)	13 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive
Insmed	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regeneron Pharmaceuticals	$14.34B	5.28	$4.50B	$40.46	18.17
Insmed	$606.42M	39.19	-$1.28B	-$4.11	N/A

Regeneron Pharmaceuticals has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Insmed has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Insmed's net margin of -76.94%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%
Insmed	-76.94%	-123.94%	-44.30%

Regeneron Pharmaceuticals currently has a consensus price target of $809.50, indicating a potential upside of 10.13%. Insmed has a consensus price target of $200.57, indicating a potential upside of 84.31%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.69
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Regeneron Pharmaceuticals beats Insmed on 10 of the 17 factors compared between the two stocks.

How does Insmed compare to argenex?

Insmed (NASDAQ:INSM) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

60.3% of argenex shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 2.4% of argenex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.19	-$1.28B	-$4.11	N/A
argenex	$4.25B	13.57	$1.29B	$26.04	35.38

argenex has a net margin of 32.19% compared to Insmed's net margin of -76.94%. argenex's return on equity of 43.59% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
argenex	32.19%	43.59%	36.66%

Insmed presently has a consensus price target of $200.57, indicating a potential upside of 84.31%. argenex has a consensus price target of $1,158.61, indicating a potential upside of 25.76%. Given Insmed's stronger consensus rating and higher possible upside, research analysts plainly believe Insmed is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
argenex	0 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.88

Insmed has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, argenex has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

In the previous week, Insmed had 2 more articles in the media than argenex. MarketBeat recorded 5 mentions for Insmed and 3 mentions for argenex. Insmed's average media sentiment score of 0.59 beat argenex's score of 0.05 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

argenex beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Insmed compare to Moderna?

Moderna (NASDAQ:MRNA) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Insmed has a net margin of -76.94% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Insmed	-76.94%	-123.94%	-44.30%

In the previous week, Moderna had 40 more articles in the media than Insmed. MarketBeat recorded 45 mentions for Moderna and 5 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Moderna's score of 0.27 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	9 Very Positive mention(s)	16 Positive mention(s)	9 Neutral mention(s)	10 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Moderna currently has a consensus price target of $77.83, indicating a potential downside of 57.96%. Insmed has a consensus price target of $200.57, indicating a potential upside of 84.31%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Moderna has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Insmed has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Insmed has lower revenue, but higher earnings than Moderna. Insmed is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	38.02	-$2.82B	-$7.99	N/A
Insmed	$606.42M	39.19	-$1.28B	-$4.11	N/A

75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Insmed beats Moderna on 9 of the 17 factors compared between the two stocks.

How does Insmed compare to Natera?

Natera (NASDAQ:NTRA) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Natera has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Insmed has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

In the previous week, Natera had 3 more articles in the media than Insmed. MarketBeat recorded 8 mentions for Natera and 5 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Natera's score of 0.50 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera currently has a consensus price target of $341.55, suggesting a potential downside of 15.37%. Insmed has a consensus price target of $200.57, suggesting a potential upside of 84.31%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

99.9% of Natera shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 2.1% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Natera has a net margin of -7.11% compared to Insmed's net margin of -76.94%. Natera's return on equity of -11.38% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
Insmed	-76.94%	-123.94%	-44.30%

Natera has higher revenue and earnings than Insmed. Natera is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	25.23	-$208.16M	-$1.36	N/A
Insmed	$606.42M	39.19	-$1.28B	-$4.11	N/A

Summary

Natera beats Insmed on 10 of the 16 factors compared between the two stocks.

How does Insmed compare to Revolution Medicines?

Insmed (NASDAQ:INSM) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Insmed has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 7.6% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Revolution Medicines' return on equity of -88.20% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Revolution Medicines	N/A	-88.20%	-57.85%

Revolution Medicines has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.19	-$1.28B	-$4.11	N/A
Revolution Medicines	$11.58M	3,807.37	-$1.13B	-$8.82	N/A

Insmed currently has a consensus price target of $200.57, suggesting a potential upside of 84.31%. Revolution Medicines has a consensus price target of $234.33, suggesting a potential upside of 13.92%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.96

In the previous week, Revolution Medicines had 11 more articles in the media than Insmed. MarketBeat recorded 16 mentions for Revolution Medicines and 5 mentions for Insmed. Insmed's average media sentiment score of 0.59 beat Revolution Medicines' score of 0.57 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Insmed on 9 of the 16 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INSM vs. The Competition

Export

Metric	Insmed	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.76B	$3.93B	$7.22B	$13.08B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-26.47	13.45	272.64	25.80
Price / Sales	39.19	1,294.15	607.49	90.99
Price / Cash	N/A	121.76	77.38	51.29
Price / Book	31.45	16.65	10.88	6.26
Net Income	-$1.28B	-$22.67M	$3.50B	$360.95M
7 Day Performance	-7.65%	-2.45%	-2.03%	-1.81%
1 Month Performance	-14.07%	-10.31%	-6.43%	-4.03%
1 Year Performance	-28.78%	21.98%	8.95%	2.18%

Insmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INSM Insmed	3.6153 of 5 stars	$108.91 +0.3%	$200.57 +84.2%	-26.3%	$23.81B	$606.42M	N/A	1,664	Analyst Forecast
REGN Regeneron Pharmaceuticals	4.2687 of 5 stars	$798.17 +1.7%	$802.18 +0.5%	+22.5%	$80.80B	$14.34B	19.73	15,410	Trending News Analyst Forecast
ARGX argenex	4.5136 of 5 stars	$988.20 -0.2%	$1,158.61 +17.2%	+22.0%	$61.96B	$4.25B	37.95	1,863
MRNA Moderna	1.9856 of 5 stars	$172.94 +12.3%	$76.72 -55.6%	+584.6%	$61.50B	$1.94B	N/A	4,700	Trending News Analyst Downgrade
NTRA Natera	2.1107 of 5 stars	$370.64 +0.3%	$330.83 -10.7%	+152.8%	$53.25B	$2.71B	N/A	6,140	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INSM) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insmed (INSM) Competitors

INSM vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Insmed compare to Regeneron Pharmaceuticals?

Summary

How does Insmed compare to argenex?

Summary

How does Insmed compare to Moderna?

Summary

How does Insmed compare to Natera?

Summary

How does Insmed compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insmed (INSM) Competitors

INSM vs. REGN, ARGX, MRNA, NTRA, and RVMD

How does Insmed compare to Regeneron Pharmaceuticals?

Does the media refer more to REGN or INSM?

Which has preferable valuation & earnings, REGN or INSM?

Which has more volatility and risk, REGN or INSM?

Do insiders and institutionals have more ownership in REGN or INSM?

Is REGN or INSM more profitable?

Do analysts recommend REGN or INSM?

Summary

How does Insmed compare to argenex?

Do insiders & institutionals believe in INSM or ARGX?

Which has higher valuation and earnings, INSM or ARGX?

Is INSM or ARGX more profitable?

Do analysts rate INSM or ARGX?

Which has more volatility and risk, INSM or ARGX?

Does the media prefer INSM or ARGX?

Summary

How does Insmed compare to Moderna?

Is MRNA or INSM more profitable?

Does the media favor MRNA or INSM?

Do analysts prefer MRNA or INSM?

Which has more risk & volatility, MRNA or INSM?

Which has better valuation and earnings, MRNA or INSM?

Do institutionals & insiders have more ownership in MRNA or INSM?

Summary

How does Insmed compare to Natera?

Which has more risk & volatility, NTRA or INSM?

Does the media favor NTRA or INSM?

Do analysts rate NTRA or INSM?

Do insiders and institutionals hold more shares of NTRA or INSM?

Is NTRA or INSM more profitable?

Which has higher valuation & earnings, NTRA or INSM?

Summary

How does Insmed compare to Revolution Medicines?

Which has more volatility & risk, INSM or RVMD?

Do institutionals & insiders believe in INSM or RVMD?

Is INSM or RVMD more profitable?

Which has stronger valuation and earnings, INSM or RVMD?

Do analysts rate INSM or RVMD?

Does the media prefer INSM or RVMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools